Li Wei, Xu Shi, Peng Naixiong, Zhang Zejian, He Hua, Chen Ruoyu, Chen Dong, Fan Jiqing, Wang Xisheng
Department of Urology, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, China.
Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, China.
Front Oncol. 2021 Feb 26;11:634542. doi: 10.3389/fonc.2021.634542. eCollection 2021.
Clear cell renal cell carcinoma (ccRCC) is the most aggressive urologic tumor, and its incidence and diagonosis have been continuously increasing. Identifying novel molecular biomarker for inhibiting the progression of ccRCC will facilitate developing new treatment strategies. Although methyltransferase-like 7B (METTL7B) was identified as a Golgi-associated methyltransferase, the function and mechanism of METTL7B in ccRCC development and progression has not been explored. METTL7B expression were significantly upregulated in ccRCC tissues (n = 60), which significantly associated with TNM classification, tumor size, lymph node metastasis, and poor prognosis for ccRCC patients. Functional studies showed downregulation of METTL7B inhibited cell proliferation, migration , and xenograft tumor formation . In addition, METTL7B knockdown promoted cell cycle arrest at G0/G1phase and induced cellular apoptosis. Taken together, downregulation of METTL7B inhibits ccRCC cell proliferation and tumorigenesis and . These findings provide a rationale for using METTL7B as a potential therapeutic target in ccRCC patients.
透明细胞肾细胞癌（ccRCC）是最具侵袭性的泌尿系统肿瘤，其发病率和诊断率一直在持续上升。识别抑制ccRCC进展的新型分子生物标志物将有助于开发新的治疗策略。尽管甲基转移酶样7B（METTL7B）被鉴定为一种与高尔基体相关的甲基转移酶，但METTL7B在ccRCC发生和进展中的功能及机制尚未得到探索。METTL7B在ccRCC组织（n = 60）中的表达显著上调，这与TNM分类、肿瘤大小、淋巴结转移以及ccRCC患者的不良预后显著相关。功能研究表明，METTL7B的下调抑制了细胞增殖、迁移和异种移植肿瘤的形成。此外，敲低METTL7B可促进细胞周期阻滞在G0/G1期并诱导细胞凋亡。综上所述，METTL7B的下调抑制了ccRCC细胞增殖和肿瘤发生。这些发现为将METTL7B用作ccRCC患者的潜在潜在治疗靶点提供了理论依据。
